Stockscreener 앱 받기
0.45
1.98%
-0.0091
시장 영업 전:
.45
전일 마감가:
$0.4591
열려 있는:
$0.4625
하루 거래량:
4.42M
Relative Volume:
0.70
시가총액:
$151.42M
수익:
$52.29M
순이익/손실:
$-134.84M
주가수익비율:
-0.60
EPS:
-0.75
순현금흐름:
$-117.11M
1주 성능:
-9.26%
1개월 성능:
-4.26%
6개월 성능:
-10.54%
1년 성능:
-76.44%
1일 변동 폭
$0.4496
$0.4682
1주일 범위
$0.4496
$0.5127
52주 변동 폭
$0.3846
$2.84
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
명칭
Sangamo Therapeutics Inc
전화
(510) 970-6000
주소
501 CANAL BLVD., RICHMOND, CA
SGMO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.45 | 154.48M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-12-13 | 업그레이드 | Truist | Hold → Buy |
| 2024-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-07 | 재개 | Guggenheim | Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-12-16 | 재개 | H.C. Wainwright | Buy |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | SunTrust | Buy |
| 2019-08-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-10-10 | 개시 | Guggenheim | Buy |
| 2018-06-20 | 개시 | BofA/Merrill | Buy |
| 2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-10-23 | 재개 | Jefferies | Buy |
| 2013-05-03 | 개시 | BioLogic Equity Research | Sell |
| 2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-07-29 | 재확인 | Wedbush | Outperform |
| 2009-10-19 | 개시 | Brean Murray | Sell |
| 2009-10-07 | 재확인 | Leerink Swann | Outperform |
| 2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals - Yahoo Finance
Inflation Data: Is Sangamo Therapeutics Inc stock positioned well for digital economy2025 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - moha.gov.vn
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - Zenopa
Is Sangamo Therapeutics Stock Built to Withstand a Pullback? - Trefis
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - MSN
Why analysts recommend Sangamo Therapeutics Inc. (GBY) stockQuarterly Earnings Summary & Precise Buy Zone Identification - Newser
Will Sangamo Therapeutics Inc. (GBY) stock maintain strong growthBreakout Watch & Real-Time Buy Signal Alerts - Newser
Sangamo Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript - GuruFocus
Can Sangamo Therapeutics Inc. (GBY) stock attract analyst upgrades2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - Newser
Can Sangamo Therapeutics Inc. (GBY) stock reach $200 price targetPortfolio Gains Report & Low Risk High Win Rate Stock Picks - Newser
How reliable is Sangamo Therapeutics Inc. (GBY) stock dividend growth2025 Momentum Check & Expert Curated Trade Setup Alerts - Newser
How Sangamo Therapeutics Inc. (GBY) stock reacts to fiscal policiesQuarterly Trade Review & Capital Efficient Trading Techniques - Newser
SGMO SEC FilingsSangamo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
FDA grants fast track designation for Sangamo’s pain treatment By Investing.com - Investing.com Canada
How Sangamo Therapeutics Inc. (GBY) stock performs in volatility spikesMarket Growth Report & Expert Approved Momentum Trade Ideas - Newser
Sangamo Therapeutics (SGMO) Stock: Gains FDA Fast Track for ST-503 in SFN Pain Treatment - parameter.io
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 29% Price Drop - 富途牛牛
Sangamo Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - marketscreener.com
Sangamo Therapeutics (SGMO) Surges on FDA Fast Track Designation for ST-503 - GuruFocus
Sangamo (SGMO) Gains FDA Fast Track for Chronic Pain Treatment - GuruFocus
Sangamo Therapeutics secures FDA fast track for ST-503 - Traders Union
Sangamo Therapeutics receives U.S. FDA fast track designation for ST-503 - marketscreener.com
Sangamo Therapeutics (Nasdaq: SGMO) gets FDA Fast Track for ST-503 in small fiber neuropathy - Stock Titan
Sangamo Therapeutics (SGMO) Stock Analysis Report | Financials & Insights - Benzinga
Is Sangamo Therapeutics Inc. (GBY) stock a top hedge fund pick2025 Technical Patterns & High Yield Stock Recommendations - Newser
Earnings Report: Is Sangamo Therapeutics Inc. stock attractive for retirement portfolios2025 Top Gainers & Capital Efficient Trading Techniques - BỘ NỘI VỤ
Sangamo Therapeutics Q3 2025 Earnings Preview - MSN
Sangamo Therapeutics, Inc. (GBY.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
How Recent Developments Are Rewriting the Story for Sangamo Therapeutics - Yahoo Finance
With Sangamo Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
[Form 4] SANGAMO THERAPEUTICS, INC Insider Trading Activity - Stock Titan
SGMO Form 4: CEO RSU vesting and 2.05M shares owned - Stock Titan
SGMO insider reports RSU tax withholding, 696,718 shares owned - Stock Titan
What drives Sangamo Therapeutics Inc. (GBY) stock priceCandlestick Trading Patterns & High Return Investment Ideas - earlytimes.in
Sangamo rises as FDA accepts rolling submission request for gene therapy - MSN
Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive - simplywall.st
What analysts say about Sangamo Therapeutics Inc GBY stockDividend Yield Trends & The Smart Money Is Buying These Picks - earlytimes.in
Sangamo Therapeutics, Inc. (SGMO) Stock: Soars 9.95% on FDA Milestone for Gene Therapy - parameter.io
With cash running low, East Bay biotech Sangamo bets on FDA submission strategySan Francisco Business Times - The Business Journals
Sangamo Therapeutics Gets US FDA Approval to Begin Rolling BLA Submission for Fabry Gene Therapy - marketscreener.com
Sangamo Therapeutics (SGMO) Advances Fabry Disease Therapy with FDA Rolling Submission - GuruFocus
Sangamo (SGMO) Advances Gene Therapy for Fabry Disease with FDA Approval Process - GuruFocus
FDA accepts Sangamo’s rolling BLA submission for Fabry disease gene therapy - Investing.com Canada
Sangamo Therapeutics announces FDA acceptance of BLA rolling submission request - marketscreener.com
Sangamo Therapeutics Announces FDA Acceptance of Rolling Submission for Gene Therapy ST-920 for Fabry Disease Treatment - Quiver Quantitative
Sangamo stock climbs after FDA accepts BLA rolling submission request By Investing.com - Investing.com Canada
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease - The Manila Times
Sangamo (Nasdaq: SGMO) rolling ST-920 Fabry BLA accepted by FDA for accelerated review - Stock Titan
Will Sangamo Therapeutics Inc. (GBY) stock rise with strong economyWeekly Trend Report & Verified Technical Trade Signals - newser.com
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Will Sangamo Therapeutics Inc. (GBY) stock gain from green policiesQuarterly Investment Review & Safe Entry Trade Reports - newser.com
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):